A phase 3 trial has shown that retatrutide, a triple agonist, substantially lowers weight and bmi in patients with obesity or overweight. The treatment has also been reported to improve other conditions, including obstructive sleep apnea, knee osteoarthritis pain, and glycemic control. However, the specifics of the trial's outcomes, including the average weight loss and potential side effects, are not consistently detailed across reports.